Epicardial Ablation in Brugada Syndrome

• Status: Completed
• Trial end date: 2016-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This prospective study evaluates the methodology and results of epicardial mapping/ablation in a large series of consecutive selected BrS patients and to verify if RFA could normalize the consequences of a genetic disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IRCCS Policlinico S. Donato
• Treatments: Ajmaline; Lorajmine

Criteria

Inclusion Criteria:

• Patients affected by Brugada Syndrome, profiled by genetic testing, with documented spontaneous or drug-induced type I BrS ECG pattern, with symptoms attributable to ventricular arrhythmias and presenting multiple documented arrhythmic episodes

• Patients with an ICD already implanted

• Patients referred to the center for an electrophysiological study and indication to a potential concomitant radio-frequency catheter ablation (RFA) of ventricular arrhythmia or ventricular fibrillation

• Age ≥ 18

• Willingness to attend follow-up examinations

• Written informed consent to the participation in the trial

Exclusion Criteria:

• Pregnancy or breast-feeding

• Patients with low arrhythmic risk (Brugada pattern III)

• Life expectancy < 12 months.